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Abstract: Gastric cancer (GC) remains responsible for a high burden worldwide being the 
third leading cause of cancer-related mortality. Most of patients present at an advanced stage 
at diagnosis and are thus candidate to standard chemotherapy resulting in median survival of 
less than 1 year. Oligometastatic gastric cancer is an increasingly recognized clinical entity 
characterized by limited metastatic spread that has been showing to benefit from aggressive 
multimodality strategies encompassing chemotherapy and surgery. The ongoing 
RENAISSANCE/AIO-FLOT5 (NCT02578368) phase III trial is aimed at evaluating if 
neoadjuvant chemotherapy followed by surgical resection of the primary tumour and 
metastases (if suitable) could become the new standard of care for oligometastatic GC. In the 
meantime, in addition to currently available clinical parameters, the emerging 
predictive/prognostic role of biomarkers such mismatch repair deficiency/microsatellite 
instability high status needs to be specifically addressed also in this subgroup of GC to assist 
in patient selection. 
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Gastric cancer is still a major killer worldwide ranking third as leading cause of cancer-related 
mortality with 819.000 deaths in 2015 and a fatality-to-case ratio of 70%1. 
Two-thirds of patients develop advanced unresectable or metastatic disease at a some point 
during their clinical history. In this setting, platinum/fluoropyrimidine-based chemotherapy is 
the standard of care leading to a median overall survival (OS) of 9-11 months2 in HER-2 
negative disease, which extends to 14-16 months when trastuzumab is added to backbone 
chemotherapy in HER-2 positive cases3. Despite recent advances in the understanding of 
disease biology and drug development, advanced gastric cancer (AGC) remains an incurable 
disease4. In this scenario, growing evidence has suggested that a subset of carefully selected 
AGC with limited metastatic spread (so-called oligometastatic) exists that might achieve long-
term disease control from a multimodality treatment strategy. In fact, although surgical 
resection of the primary tumour in stage IV disease has been recently discouraged by 
REGATTA study5 and is not routinely recommended except for treating bleeding or 
obstruction, metastasectomies after neoadjuvant chemotherapy have gained interest following 
promising results from both clinical trials and real-world experience. In the last years, several 
lines of evidence have shown prolonged survival for selected patients undergoing liver and 
lung metastasectomies with promising 5-year OS of 27–37%6-10 and 31-33%11-12, respectively. 
Moreover, a meta-analysis of 16 studies including 1712 patients (of whom 378 patients treated 
with metastasectomy) reported increased OS at 1 (67%), 3 (32%), and 5 (25%) years for 
resection of metastases compared with other therapies (32%, 6% and 4%, respectively)13. 
Despite being quite encouraging, these results come from retrospective, uncontrolled and 
monocentric case series, enrolling mainly Asian patients, thus they have to be interpreted 
cautiously. In addition, administering neoadjuvant chemotherapy before an aggressive 
surgical approach could hopefully even result in better outcomes. Indeed, upfront treatment 
enables early administration of systemic treatment thereby preventing delays in chemotherapy 
delivery and thus maximizing the chance of benefit from systemic treatment. Still, it represents 
a tool for patient selection according to disease biology since it allows responsive patients to 
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proceed to surgery, while avoiding major risks associated to surgical procedure to less or non-
responsive ones. 
In a recent published article, Carmona-Bayonas and colleagues presented the results of a 
Spanish nationwide dataset regarding the real-world management of AGC14. The authors 
identified a subset of patients with oligometastatic disease, accounting for roughly 5% (n=92) 
of the whole population recorded over a decade. These patients showed a longer survival with 
multimodality strategy including neoadjuvant chemotherapy followed by surgical resection of 
metastases than without surgery (HR 0.34, 95%CI 0.06-0.80, p=0.021). The median OS was 
16.7 months and the 3-year OS was 30.6%, with most of patients disease-free at that time 
point. This compares very favourably with median OS and 3-year OS from historical trials of 
fist-line chemotherapy in AGC, that are in the range of 9-11 months and <10%, respectively. 
Moreover, based on a survey jointly performed by EORTC-JCOG, the preferred option for both 
resectable synchronous and metachronous liver-only disease turned out to be preoperative 
chemotherapy followed by gastrectomy and hepatic resection (47.5% of Centres)15. Although 
commonly used in community practice, this approach requires confirmation in large 
prospective randomized trials to possibly build a new evidence-base standard of care for this 
clinical subset of AGC. In the AIO/FLOT3 trial, a three-arm, prospective, non-randomized 
phase II study, Al Batran et al. enrolled onto arm B 60 patients with limited metastatic gastric 
or gastroesophageal junction adenocarcinoma to receive 4 cycles of FLOT regimen (5-
fluorouracil, oxaliplatin and docetaxel) followed by curative/life-prolonging intent surgery 
(primary tumour and metastases) if a R0 resection or at least a macroscopic complete 
metastasectomy was deemed feasible and 4 subsequent adjuvant FLOT cycles16. Patients in 
arm B had a single incurable site (e.g. liver with < 5 lesions, Krukenberg tumours, adrenal 
gland metastases) with or without retroperitoneal lymph nodes metastases, retroperitoneal 
lymph nodes metastases only, and no diffuse nor symptomatic nor clinically detectable 
peritoneal carcinomatosis. Arm A and arm C consisted of resectable and extensively 
metastatic tumours and were assigned to perioperative FLOT (4 cycles before and 4 cycles 
after surgery) and palliative FLOT, respectively. In arm B, 45% (27) of patients had only 
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retroperitoneal lymph nodes metastases, while 18.3% (11) had liver-only metastases. Among 
patients with limited metastatic spread, 36 (60%) went on to surgery with a median OS of 31.3 
months, while patients who did not undergo surgery had median OS of 15.9 months. The 
median OS was higher in arm B (22.9 months) compared to arm C (10.7 months), while in 
arm A was not yet achieved. Despite the limitations pertaining to a non-randomized trial with 
a relatively small sample size, AIO/FLOT3 should be regarded as a proof of concept study 
which set the stage for confirmatory properly design phase III clinical trials, wherein standard 
first-line palliative chemotherapy is compared to a more aggressive treatment strategy 
including neoadjuvant chemotherapy and surgical resection of metastases. One such trial, the 
RENAISSANCE/AIO-FLOT5 (NCT02578368), is actively recruiting patients with the aim of 
answering all the open questions in this setting and the results are awaited in 2021. 
Several issues need in fact to be addressed. First of all, the proper selection of AGC patients 
more likely to benefit from a combined approach is key to optimize treatment success, while 
sparing medical and surgical risks to the remaining. Although no standardized definition of 
oligometastatic GC exists, clinical criteria employed in the AIO studies provide us the 
reference on which building our clinical decision making. Moreover, younger age (≤ 70 years) 
patients with better performance status (ECOG PS 0-1), limited number of metastatic sites (< 
3 sites), and limited number (≤ 5 lesions), favourable parenchymal location (unilobar) and 
small size of hepatic lesions have been proposed as positive prognostic factors in patients 
undergoing metastasectomies6-13. However, these findings require prospective validation and 
it is currently unknown whether they also apply to patients treated with preoperative 
chemotherapy. Secondly, novel biomarkers, other than clinical parameters, are emerging and 
might be useful in selecting the optimal candidates to a combined treatment strategy. In 
resectable GC, mismatch repair deficiency (MMRd) and microsatellite instability high (MSI-H) 
status have been shown to have a positive prognostic effect in patients treated with surgery 
alone and a negative predictive value in those who received perioperative chemotherapy17. 
Accordingly, recent evidence points to a positive prognostic role for MSI-H status in surgically 
treated stage IV AGC18, though no data are available on the role of MSI status neither in 
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patients undergoing metastasectomy nor preoperative chemotherapy followed by 
metastasectomy. In the advance-disease setting, the potential predictive role of MSI status 
warrants further investigation particularly in light of the suggested benefit of oligometastatic 
GC from multimodality approach. Moreover, based on promising data on anti-PD1 nivolumab 
and pembrolizumab in heavily pretreated AGC19-20, the incorporation of immune checkpoint 
inhibitors into conventional chemotherapy regimens is currently under investigation both for 
resectable and metastatic GC and would deserve a particular focus on oligometastatic 
disease. Indeed in these patients an improvement in anticancer activity might translate in a 
higher number of patients amenable to potentially curative or life-prolonging intent surgery. 
Finally, specific mention also needs to be made to peritoneal carcinomatosis, which is one of 
the features conditioning the poorest prognosis and quality of life in AGC. Another aggressive 
multimodality treatment including cytoreductive surgery and hyperthermic intraperitoneal 
chemotherapy (in addition to systemic treatment) has been tested in this setting. However, to 
date neither definitive nor convincing efficacy data have been produced, at the expense of 
increased toxicity with procedure-related morbidity and mortality in the range of 10%-55% and 
3%-10%, respectively, in high-volume specialized centres21. Trial such as GASTRIPEC trial 
(NCT02158988) are underway to compare in a prospective randomized fashion cytoreductive 
surgery and hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery in 
properly selected AGC patients with peritoneal carcinomatosis. 
 
In summary, the concept of “oligometastases” first proposed by Hellman and Weichselbaum 
in 199522 is increasingly showing to fit GC. Oligometastatic GC is indeed an emerging clinical 
entity with potentially distinct therapeutic implications that has no standard approach thus far. 
These patients seem to benefit from multimodality treatment strategies including neoadjuvant 
chemotherapy followed by surgical resection, resulting in intermediate survival outcomes 
between those of resectable and extensively metastatic GC (Figure 1). More interestingly, 
there is also hope to achieve not just long-term disease control but also curability at least in a 
proportion of them. Results of ongoing randomized phase III clinical trials are eagerly awaited 
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in order to clarify whether an aggressive multimodality approach could become a new standard 
of care in highly selected patients with oligometastatic GC. 
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Figure 1. Treatment plan and survival outcomes according to clinical stage in gastric 
cancer. 
12 
 
 
 
 
 
 
 
 
 
  
 
